Stay updated on 177Lu-DOTA-rosopatamab vs SoC in PSMA+ mCRPC: Clinical Trial
Sign up to get notified when there's something new on the 177Lu-DOTA-rosopatamab vs SoC in PSMA+ mCRPC: Clinical Trial page.

Latest updates to the 177Lu-DOTA-rosopatamab vs SoC in PSMA+ mCRPC: Clinical Trial page
- Check2 days agoChange DetectedRevision: v3.5.2 was added, replacing the previous v3.5.0.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange Detected- Revision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check38 days agoChange DetectedA new revision entry v3.4.3 was added to the record history. The previous revision v3.4.2 was removed from the history.SummaryDifference0.1%

- Check53 days agoChange DetectedTelix is conducting a separate Phase 3 trial (NCT06520345) under an IND, which necessitates the closure of the current 177Lu-TLX591-002 Phase 3 trial. The record now shows the study as Terminated and indicates that the prior Recruiting status was removed.SummaryDifference1.0%

- Check67 days agoChange DetectedNew system Revision: v3.4.2 has been added to the record history, and the prior government funding lapse notice has been removed.SummaryDifference0.9%

- Check74 days agoChange DetectedA site-wide notice about government funding and an updated Revision: v3.4.1 were added, and the previous Revision: v3.4.0 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

Stay in the know with updates to 177Lu-DOTA-rosopatamab vs SoC in PSMA+ mCRPC: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the 177Lu-DOTA-rosopatamab vs SoC in PSMA+ mCRPC: Clinical Trial page.